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ABSTRACT
BAYESIAN DESIGNS FOR EARLY PHASE CLINICAL TRIALS WITH NOVEL
TARGETED AGENTS
Heng Zhou, M.S.
Advisory Professor: Ying Yuan, Ph.D.
My dissertation mainly focus on Bayesian designs for early phase clinical trials with
novel target agents. It includes three specific topics: (1) reviewing novel phase I
clinical trial designs and comparing their operating characteristics; (2) Proposing a
Bayesian optimal phase II clinical trial (BOP2) design with simple and complex end-
points under a unified framework; and (3) extending the BOP2 design to incorporate
the durable clinical response as a primary endpoint.
A number of novel model-based and model-assisted designs have been proposed to
find the maximum tolerated dose (MTD) in phase I clinical trials, but their differ-
ences and relative pros and cons are not clear to many practitioners. We review
three model-based designs, including the continual reassessment method (CRM),
dose escalation with overdose control (EWOC), and Bayesian logistic regression
model (BLRM), and three model-assisted designs, including the modified toxicity
probability interval (mTPI), Bayesian optimal interval (BOIN), and keyboard de-
signs. We conduct numerical studies to assess their accuracy, safety and reliability,
and the practical implications of various empirical rules used in some designs, such as
skipping a dose and imposing overdose control. Our results show that the CRM out-
performs EWOC and BLRM with higher accuracy of identifying the MTD. For the
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CRM, skipping a dose is not recommended as it substantially increases the chance of
overdosing patients, while providing limited gain for identifying the MTD. EWOC
and BLRM appear excessively conservative. They are safe, but have relatively poor
accuracy of finding the MTD. The BOIN and keyboard designs have similar oper-
ating characteristics, outperforming the mTPI, but the BOIN is more intuitive and
transparent. The BOIN yields competitive performance comparable to the CRM, but
is simpler to implement and free of the issue of irrational dose assignment caused by
model misspecification, thereby providing an attractive approach for designing phase
I trials.
We propose a flexible Bayesian optimal phase II (BOP2) design that is capable of
handling simple (e.g., binary) and complicated (e.g., ordinal, nested and co-primary)
endpoints under a unified framework. We use a Dirichlet-multinomial model to ac-
commodate different types of endpoints. At each interim, the go/no-go decision is
made by evaluating a set of posterior probabilities of the events of interest, which
is optimized to maximize power or minimize the number of patients under the null
hypothesis. Unlike most existing Bayesian designs, the BOP2 design explicitly con-
trols the type I error rate, thereby bridging the gap between Bayesian designs and
frequentist designs. In addition, the stopping boundary of the BOP2 design can be
enumerated prior to the onset of the trial. These features make the BOP2 design
accessible to a wide range of users and regulatory agencies, and particularly easy to
implement in practice. Simulation studies show that the BOP2 design has favorable
operating characteristics with higher power and lower risk of incorrectly terminating
the trial than some existing Bayesian phase II designs. The software to implement
the BOP2 design is freely available at www.trialdesign.org.
Based on the BOP2 design, we propose a BOP2-C design which jointly models the
vi
nested efficacy endpoints and the long-term durable clinical response (cure rate)
simultaneously. We use a Dirichlet-multinomial model to account for the tumor re-
sponse CR, PR, SD and PD, and assume Weibull distribution on the time to disease
progression in the non-cured patients. At each interim, the go/no-go decision is made
based on the posterior estimation of the CR, CR/PR and cure rates, with the opti-
mized design parameters in the posterior probability cutoffs varying with the interim
sample size. The BOP2-C design can also explicitly control the type I and type II
error rates. Simulation studies show that the BOP2-C design can achieve favorable
operating characteristics with high accuracy in identifying the promising treatment,
and it is still robust when the true distribution of time to disease progression violates
the Weibull assumption.
vii
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CHAPTER 1
Introduction
As the groundbreaking achievement in novel molecular targeted agents and
cancer immunotherapy in recent years, novel early phase (both phases I and II) clin-
ical trial designs have been developed in order to deal with more complex endpoints
and improve design efficiency compared to traditional designs. Phase I clinical trial
designs aim to identify the maximum tolerated dose (MTD) of a new drug, which is
defined as the dose with a dose-limiting toxicity (DLT) probability which is closest to
the target DLT probability. The 3+3 design [1] has been dominant in phase I clinical
trials for decades due to its simplicity and transparency, despite its poor ability to
identify the MTD and tendency to treat patients at low doses that are potentially
subtherapeutic [2]. The 3+3 design and its variations are called algorithm-based
designs because they use simple, prespecified rules to guide dose escalation. The
extensions of 3+3 design include the “rolling-six” design [3], the biased-coin design
[4] and its variations [5, 6]. Model-based designs have been proposed that improve
upon the performance of algorithm-based designs. The most well known model-
based design is the continual reassessment method (CRM) [7]. The CRM assumes
a parametric model for the dose-toxicity curve, and then, based on the accumu-
lating trial data, continuously updates the estimate of the curve to guide the dose
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assignment and MTD selection. Various extensions of the CRM have been proposed,
including dose escalation with overdose control (EWOC) [8], Bayesian logistic regres-
sion model (BLRM) [9], time-to-event CRM [10], Bayesian model averaging CRM
[11], Bayesian data-augmentation CRM [12], partial order CRM [13], and bivariate
CRM [14]. Cheung provides a comprehensive review of the CRM and its related
methods [15]. Compared to algorithm-based designs, model-based designs typically
have superior operating characteristics. However, its use in practice has been limited
probably due to its requirement of repeated model-fitting, its conceptual and compu-
tational complexity, and its non-transparent approach to decision making. Recently,
a new class of designs, known as model-assisted designs [16], have been proposed to
combine the simplicity of algorithm-based designs with the superior performance of
model-based designs. Model-assisted designs use a model for efficient decision mak-
ing like model-based designs, while their dose escalation and de-escalation rules can
be tabulated before the onset of a trial as with algorithm-based designs. Examples
of model assisted designs include the modified toxicity probability interval (mTPI)
design [17] and its variation mTPI-2 [18], Bayesian optimal interval (BOIN) design
[19, 20], keyboard design [16], BOIN combination design [21] and phase I/II design
[22, 23], and keyboard combination design [24]. Mu et al. [25] proposed a general-
ized BOIN (gBOIN) design that handle toxicity grades, binary or continuous toxicity
endpoint under a unified framework.
Phase II clinical trials are usually single-arm studies aimed at estimating the
efficacy of a new treatment. They are designed to warrant efficacious treatments to
be sent into large-scale randomized Phase III trials [26]. The primary endpoint for
phase II clinical trial is usually patient’s response to the new treatment, which is
a binary outcome (response/no response). Extensive statistical methods have been
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developed for Phase II clinical trial designs. A fundamental feature of phase II clin-
ical trial designs is that they allow early termination before the maximum sample
size is reached if the treatment is expected to be futile given the current observed
data. Numerous designs, either frequentist or Bayesian, have been developed for
phase II clinical trials. Among the frequentist designs, the most well known is Si-
mon’s optimal two-stage design [27], which minimizes the expected sample size or
the maximum sample size under the null hypothesis that the treatment is not effec-
tive, while controlling the type I and II error rates at desirable levels. Other related
work includes Fleming’s multiple-stage test [28], Ensign’s optimal three-stage design
[29], and Chen’s optimal three-stage design [30], among others. The major limitation
of such fixed-stage methods is that they have rigorous prespecified requirements on
each stage. However there is often disparity between proposed design and actual
trial conduct [31, 32]. Bayesian approach could offer more flexible designs by up-
dating information only from treated patients but not related with design setups.
It also allows more flexible patient enrollment mechanism. Thall and Simon (1994)
proposed a Bayesian guideline of continuously monitoring the posterior probability
of whether the new treatment is promising or not, which is simple and intuitive [33].
Other Bayesian phase II trial designs developed based on the posterior probability
include Heitjan’s design which suggested the use of a “persuasion probability” as a
consistent criterion for assessing if the new treatment is promising or not [34]. Tan
and Machin [35] proposed two Bayesian two-stage designs that mimic Simon’s two-
stage design. Lee and Liu (2008) proposed a Bayesian phase II clinical trial design
based on the predictive probability instead of the posterior probability [36].
Cancer immunotherapy is a promising treatment that stimulates the immune
system to battle against cancer in the human body [37, 38, 39]. It has been shown
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that cancer immunotherapy can achieve desirable clinical response in multiple types
of cancer, including advanced melanoma, renal cell cancer, and non-small-cell lung
cancer [40, 41, 42], etc. The mainstream cancer immunotherapeutic approaches in-
clude monoclonal antibodies (mAbs), immune checkpoint inhibitors, cancer vaccines,
and other non-specific immunutherapies. A handful of clinical trials have indicated
that cancer immunotherapy can achieve long-term survival and durable tumor re-
sponse — rather than short-term objective tumor response — in a subset of patients.
Although the proportion of patients may be small, such results could give researchers
more insight to identify the unknown biomarkers that predict the durable clinical re-
sponse to the treatment. Therefore, such durable clinical response should be served
as a desirable endpoint in clinical trials, despite that it usually occurs in a small
subset of patients, and more patients would experience low response rates and high
toxicities [43].
This dissertation is organized as follows. In chapter 2, we will review several
novel phase I clinical trial designs, compare their operating characteristics using
the traditional 3+3 design as the benchmark. We conduct numerical studies to
assess their accuracy, safety and reliability, and the practical implications of various
empirical rules used in some designs, such as skipping a dose and imposing overdose
control. In chapter 3, we propose a flexible Bayesian optimal phase II (BOP2) design
that is capable of handling simple (e.g., binary) and complicated (e.g., nested, co-
primary and eff&tox) endpoints under a unified framework. In chapter 4, we propose
an extension to the BOP2 design which incorporates the durable clinical response of
cancer immunotherapy for phase II clinical trials. Chapter 5 is conclusion and future
work.
4
CHAPTER 2
Novel phase I clinical trial designs
2.1 Introduction
The development of the novel phase I clinical trial designs provides practi-
tioners an array of tools for conducting more flexible and efficient phase I trials. We
seek to compare these designs to determine their differences and relative pros and
cons. In addition, some designs (e.g., CRM and BLRM) suggest optional empirical
rules to regulate dose escalation, such as whether dose skipping should be allowed
or an overdose control rule should be applied. Based on our experience with phase
I trials at the Food and Drug Administration and MD Anderson Cancer Center,
we observe that some protocols impose these empirical rules, while others do not.
The practical implications of these empirical rules are not clear. To fill these knowl-
edge gaps, we reviewed several novel phase I designs, the model-based CRM, EWOC
and BLRM designs, and model-assisted mTPI, BOIN, and keyboard designs, and
conducted a Monte Carlo experiment (i.e., computer simulations) to compare their
operating characteristics. We note that mTPI-2 ends up with the same design as
the keyboard design, thus the results for keyboard design also apply to mTPI-2.
Another important issue that we examined but which is largely overlooked in the
existing literature is the reliability of the design, which is defined as the likelihood of
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extreme problematic trial behavior occurring under a design [19], for example, the
likelihood of a design overdosing more than 50% of the patients, and the likelihood
of a design failing to de-escalate the dose when 2/3 or ≥3/6 patients had DLTs at
that dose. The incidence of such extreme behavior in a trial design may be low,
but is of serious practical concern when it occurs. Our study reveals some new, in-
triguing design behaviors that have important practical implications. For example,
two designs may have similar performance in some commonly used metrics (e.g., the
average number of patients treated above the MTD), but rather different likelihood
of overdosing more than 50% of the patients and failing to de-escalate the dose when
2/3 or ≥3/6 patients had DLTs.
Several simulation studies were carried out to compare the operating char-
acteristics of novel phase I designs, but based on a limited number of dose-toxicity
scenarios (or curves). For example, Horton, Wages and Conaway [44] compared the
CRM, mTPI and BOIN designs in a simulation study with 16 dose-toxicity scenar-
ios, and Ananthakrishnan et al. [45] considered only 3 dose-toxicity scenarios with
the MTD at the same dose level. As a result, these simulation studies are prone to
inadvertent selection biases of the simulation scenarios and produce the results that
may not represent the general performance of the designs. In this chapter, we con-
duct a large scale simulation study that includes 1000 dose-toxicity scenarios. These
1000 dose-toxicity scenarios are randomly generated using a new pseudo-uniform al-
gorithm, recently proposed by Clertant and O’Quigley [46]. Because a priori that
algorithm does not favor any particular dose as the MTD or a particular shape of
the dose-toxicity curve, it provides a neutral and objective basis for comparison.
6
2.2 Methods
Before reviewing the designs, we establish notation. We use d1 < · · · < dJ
to denote the J prespecified doses of the new drug that is under investigation in the
trial, pj to denote the DLT probability that corresponds to dj, and φ to denote the
target DLT probability for the MTD. We use nj to denote the number of patients
who have been assigned to dj, and yj to denote the number of DLTs observed at
dj, j = 1, . . . , J . Therefore, at a particular point during the trial, the observed data
are D = {Dj, j = 1, . . . , J}, where Dj = (nj, yj) are the “local” data observed at
dose level j. For completeness and illustrating the differences between model-based
and model-assisted designs, we first briefly describe the CRM, EWOC and BLRM
designs, followed by the mTPI, keyboard and BOIN designs.
2.2.1 Continual reassessment method
The CRM is a model-based dose-finding approach that assumes a paramet-
ric model for the dose-toxicity curve. As information accrues during the trial, the
dose-toxicity curve is re-evaluated by updating the estimates of the unknown model
parameters, and the corresponding DLT probability at each investigational dose. The
current estimates for the DLT probabilities are used to determine the dose allocation
for the next patient or cohort of patients. One commonly used model for the CRM
is the power model (also known as the empiric model) that assumes,
(2.1) pj(α) = a
exp(α)
j , for j = 1, . . . , J,
where α is the unknown parameter and 0 < a1 < · · · < aJ < 1 are prior guesses
for the DLT probability at each dose. The {aj, j = 1, . . . , J} often are called the
“skeleton” of CRM.
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Under the power model in (2.1), the likelihood function for α arises as,
L(α |D) =
J∏
j=1
{
a
exp(α)
j
}yj {
1− aexp(α)j
}nj−yj
,
and thus, the posterior mean estimate for pj is calculated as,
pˆj =
∫
a
exp(α)
j
L(α |D) f(α)∫
L(α |D) f(α) dα dα,
where f(α) denotes the prior distribution for α, e.g., N(0, 2). Upon updating the
posterior mean estimate of the DLT probability at each dose, the next patient or co-
hort of patients is assigned to the “optimal” dose with an estimated DLT probability
closest to the target φ. That is, the next patient or cohort of patients is assigned to
dose level j∗ such that
j∗ = argmin
j∈(1,...,J)
|pˆj − φ|.
As illustrated in Figure 2.1a, the observation of DLTs tends to lift the dose-toxicity
curve, leading to dose de-escalation; and the observation of no DLT tends to lower
the dose-toxicity curve, leading to dose escalation. The trial continues in this manner
until the prespecified sample size is exhausted. At that point, the MTD is selected as
the dose with an estimated DLT probability closest to the target φ. In the original
CRM, new patients are always assigned to the currently estimated “optimal” dose,
which may lead to skipping untried doses. In practice, many trials impose a rule that
forbids skipping doses and restricts dose escalation and de-escalation to one level at a
time. In addition, a safety stopping rule is included such that the trial is terminated
if Pr(p1 > φ |D) > 0.95 (i.e., the lowest dose d1 has more than 95% chance of being
above the MTD). We imposed these practical rules for the CRM in our simulation
study.
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2.2.2 Dose escalation with overdose control (EWOC)
The EWOC is a modification of the CRM [8]. The EWOC employs a two-
parameter logistic regression model to provide extra flexibility to model the dose-
toxicity curve,
(2.2) logit(pj) = β0 + β1dj, β1 > 0, j = 1, . . . , J,
where β0, β1 are the unknown intercept and slope parameters, and dj is the raw
dosage at dose level j. To facilitate the interpretation, the EWOC reparameterizes
the two-parameter logistic model using the MTD γ and the DLT probability at the
first dose (i.e., p1), as follows:
γ =
1
β1
(log(φ)− log(1− φ)− β0) ,(2.3)
p1 =
exp(β0 + β1d1)
1 + exp(β0 + β1d1)
.(2.4)
The EWOC starts by treating the first cohort of patients at the lowest dose
d1. After each patient cohort is treated, the EWOC updates the estimate of the
dose-toxicity curve based on the accumulating DLT data across all dose levels, and
assigns the next cohort of patients to the “optimal” dose, defined as the highest dose
whose posterior probability of greater than the MTD γ is equal to or less than α,
i.e., Pr(dj > γ |D) ≤ α, with the recommended value of α = 0.25. In the EWOC,
dose skipping is not allowed. Thus, if the estimated optimal dose is higher than the
current dose, we escalate the dose for one level; of the estimated optimal dose is
lower than the current dose, we de-escalate the dose for one level. In our simulation,
we used the same safety stopping rule as the CRM for the EWOC, i.e., the trial will
be terminated if Pr(p1 > φ |D) > 0.95.
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2.2.3 Bayesian logistic regression model (BLRM)
The BLRM is another modification of the CRM [9]. The BLRM uses the
similar two-parameter logistic regression model as the EWOC such that:
(2.5) logit(pj) = logα + β log(
dj
d∗
), α, β > 0, j = 1, . . . , J,
where α, β are unknown parameters, dj is the raw dosage at dose level j, and d
∗ is
the reference dosage. The BLRM requires defining the proper dosing interval (δ1, δ2),
defined as the range of DLT probabilities regarded as acceptable. For example, given
target φ = 0.25, the interval (0.2, 0.3) may be defined as the proper dosing interval.
The BLRM imposes an overdose control rule as follows: if the observed data suggest
that there is ≥25 posterior probability that the DLT rate of a dose is greater than
δ2, i.e., Pr(pj > δ2 |D) ≥ 0.25, that dose is an overdose and cannot be used to treat
patients.
The BLRM starts the trial by treating the first cohort of patients at the lowest
dose d1. After each patient cohort is treated, the BLRM updates the estimate of the
dose-toxicity curve based on the accumulating DLT data across all dose levels, and
assigns the next cohort of patients to the optimal dose. Under the above overdose
control rule, the optimal dose is defined as the dose level j that satisfies the overdose
control condition Pr(pj > δ2 |D) ≥ 0.25 and meanwhile maximizes the posterior
probability of the proper dosing interval (δ1, δ2), i.e., Pr(pj ∈ (δ1, δ2) |D). In BLRM,
dose skipping is not allowed. Thus, if the estimated optimal dose is higher than
the current dose, we escalate the dose for one level; of the estimated optimal dose is
lower than the current dose, we de-escalate the dose for one level. The above overdose
control rule leads to the following safety stopping rule: stop the trial if the lowest
dose is an overdose. That is, the trial will be terminated if Pr(p1 > δ2 |D) ≥ 0.25.
10
We also consider removing the overdose control rule of the BLRM, and name
it BLRM-NOC. For the BLRM-NOC, the “optimal” dose is defined as the dose
that maximizes the posterior probability of the proper dosing interval (δ1, δ2), i.e.,
Pr(pj ∈ (δ1, δ2) |D). For the BLRM-NOC, the safety stopping rule described above
cannot be used because it does not use the overdose control rule. Thus, in BLRM-
NOC, we used the same safety stopping rule as the CRM, i.e., the trial will be
terminated if Pr(p1 > φ |D) > 0.95.
2.2.4 Modified toxicity probability interval (mTPI) design
The mTPI design requires the investigator to prespecify three intervals, the
underdosing interval (0, δ1), the proper dosing interval (δ1, δ2), and the overdosing
interval (δ2, 1). For example, given a target rate of φ = 0.20, the three intervals may
be defined as (0, 0.15), (0.15, 0.25), and (0.25, 1), respectively. The mTPI design
assumes
yj |nj, pj ∼ Binom(nj, pj)(2.6)
pj ∼ Beta(1, 1) ≡ Unif(0, 1)
i.e., a beta-binomial model, and thus, the posterior distribution arises as,
(2.7) pj |Dj ∼ Beta(yj + 1, nj − yj + 1), for j = 1, . . . , J.
Unlike the CRM, which models the toxicity across doses using the power model (2.1),
the mTPI models toxicity only at the current dose dj. To determine the next dose,
based on Dj, the mTPI design uses the unit probability mass (UPM) corresponding
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to each of the three intervals, which are defined as,
(2.8)
UPM1 = Pr(pj ∈ (0, δ1) |Dj) /δ1 ,
UPM2 = Pr(pj ∈ (δ1, δ2) |Dj) /(δ2 − δ1) ,
UPM3 = Pr(pj ∈ (δ2, 1) |Dj) /(1− δ2) .
That is, the UPM is the posterior probability that pj lies in the corresponding interval
divided by the length of that interval. Graphically, the UPM of an interval is the
area under the posterior distribution curve of pj within the interval divided by the
interval length (see Figure 2.1b)
Suppose j is the current dose level. The mTPI design determines the next
dose as follows:
• If UPM1 = max{UPM1,UPM2,UPM3}, then escalate the dose to level j + 1.
• If UPM2 = max{UPM1,UPM2,UPM3}, then stay at the current dose level j.
• If UPM3 = max{UPM1,UPM2,UPM3}, then de-escalate the dose to level j−1.
Because the three UPMs can be determined for all possible outcomes Dj =
(nj, yj), the dose escalation and de-escalation rules can be tabulated before the trial
begins, which makes the mTPI design easy to implement in practice. The trial
continues until the prespecified sample size is exhausted. At that point, the MTD
is selected based on isotonic estimates of the pj that are calculated using the pooled
adjacent violators algorithm [47]. As the decision of dose escalation and de-escalation
is based only on the local data at the current dose, it is possible that the dose
transition oscillates between a safe dose and the next higher dose that is toxic. To
avoid that issue, the mTPI design includes a dose exclusion/safety stopping rule: if
Pr(pj > φ | nj, yj) > 0.95, dose level j and higher are excluded from the trial. If the
lowest dose is excluded, the trial is stopped for safety.
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One drawback of using the UPM to guide dose escalation is that it lacks clear
interpretation and leads to a high risk of overdosing patients [16]. To see the problem,
consider a trial with a target toxicity rate of 0.20, and underdosing, proper dosing,
and overdosing intervals of (0, 0.17), (0.17, 0.23), and (0.23, 1), respectively. Suppose
at a certain stage of the trial, the observed data indicate that the posterior proba-
bilities of the underdosing interval, proper dosing interval, and overdosing interval
are 0.01, 0.09, and 0.9, respectively. That is, there is a 90% chance that the current
dose is overdosing patients and only a 9% chance that the current dose is properly
dosing patients. Despite such dominant evidence of overdosing, the mTPI design
stays the same dose for treating the next patient or patient cohort, since the UPM
that corresponds to the proper dosing interval is the largest. In particular, the UPM
that corresponds to the proper dosing interval is 0.09/(0.23 − 0.17) = 1.5, whereas
the UPM that corresponds to the overdosing interval is 0.9/(1− 0.23) = 1.17.
2.2.5 Keyboard design
The keyboard design [16] resolves the overdosing issue of the mTPI by defining
a series of equal-width dosing intervals (or keys) that correspond to the potential
locations of the true DLT probability of a particular dose, and using the interval (or
key) with the highest posterior probability to guide dose escalation and de-escalation,
see Figure 2.1d. Specifically, the keyboard design starts by specifying a proper dosing
interval I∗ = (δ1, δ2), referred to as the “target key”, and then populates this interval
toward both sides of the target key, forming a series of keys of equal width that span
the range of 0 to 1. For example, given the proper dosing interval or target key
of (0.25, 0.35), on its left side, we form 2 keys of width 0.1, i.e., (0.15, 0.25) and
(0.05, 0.15); and on its right side, we form 6 keys of width 0.1, i.e., (0.35, 0.45),
(0.45, 0.55), (0.55, 0.65), (0.65, 0.75), (0.75, 0.85) and (0.85, 0.95). We denote the
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resulting intervals/keys as I1, · · · , IK . As all keys have the equal width and must be
within [0, 1], some DLT probability values at the two ends (e.g., < 0.05 or > 0.95 in
the example) may not be covered by keys because they are not long enough to form
a key. As explained in Yan et al. [16], ignoring these “residual” DLT probabilities
at the two ends does not pose any issue for decision making of dose escalation and
de-escalation.
To make the decision of dose escalation and de-escalation, given the observed
data Dj = (nj, yj) at the current dose level j, the keyboard design identifies the
interval Imax that has the largest posterior probability, i.e.,
Imax = argmax
I1,··· ,IK
{Pr(pj ∈ Ik |Dj); k = 1, · · · , K},
which can easily be evaluated based on pj’s posterior distribution given by equation
(2.7), assuming that pj follows a beta-binomial model (2.6). Imax represents the
interval that the true value of pj is most likely located, referred to as the “strongest”
key by Yan et al. [16]. Graphically, the strongest key is the one with the largest
area under the posterior distribution curve of pj (see Figure 2.1d). If the strongest
key is on the left (or right) side of the target key, that means that the observed data
suggest that the current dose is most likely underdosing (or overdosing), and thus
dose escalation (or de-escalation) is needed. If the strongest key is the target key,
the observed data support that the current dose is most likely to be in the proper
dosing interval, and thus it is desirable to retain the current dose for treating the
next patient. In contrast, the UPM used by the mTPI design does not have such an
intuitive interpretation and tends to distort the evidence for overdosing, as described
previously.
Suppose j is the current dose level. The keyboard design determines the next
dose as follows:
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• If the strongest key is on the left side of the target key, then escalate the dose
to level j + 1.
• If the strongest key is the target key, then stay the current dose level j.
• If the strongest key is on the right side of the target key, then de-escalate the
dose to level j − 1.
The trial continues until the prespecified sample size is exhausted, and the MTD is
selected based on isotonic estimates of pj as described previously. During the trial
conduct, the keyboard design imposes the dose exclusion/early stopping rule such
that: if Pr(pj > φ | nj, yj) > 0.95 and nj ≥ 3, dose level j and higher are eliminated
from the trial, and the trial is terminated if the lowest dose is eliminated, where
Pr(pj > φ | nj, yj) is evaluated based on the posterior distribution (2.7).
Similar to the mTPI design, the dose escalation and de-escalation rules of the
keyboard design can be tabulated before the trial begins, making it easy to implement
in practice. As the location of the strongest key approximately indicates the mode
of the posterior distribution of pj, the keyboard design can be approximately viewed
as a posterior-mode-based Bayesian dose-finding method. This makes the keyboard
design a new method different from the UPM-based mTPI design, despite some
structural similarities between two designs (e.g., partitioning the toxicity probability
into intervals and the dose escalation and de-escalation rules can be pre-tabulated).
Pan, Lin and Yuan [24] showed that the keyboard design is optimal under the 0-1
loss, long-memory coherent and extended it to drug-combination trials.
2.2.6 Bayesian optimal interval (BOIN) design
Compared to the mTPI and keyboard designs, the BOIN design is more
straightforward and transparent. The dose escalation and de-escalation in the BOIN
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design is determined simply by comparing the observed DLT rate at the current
dose with a pair of fixed dose escalation and de-escalation boundaries. Specifically,
let pˆj = yj/nj denote the observed DLT rate at the current dose, and λe and λd
denote the predetermined dose escalation and de-escalation boundaries. Suppose j
is the current dose level. The BOIN design determines the next dose as follows (see
Figure 2.1c):
• If pˆj ≤ λe, then escalate the dose to level j + 1;
• If pˆj ≥ λd, then de-escalate the dose to level j − 1;
• Otherwise (i.e., λe < pˆj < λd), stay at the current dose level j.
The trial continues until the prespecified sample size is exhausted. At that point,
select the MTD based on the isotonic estimates of DLT probabilities as described
previously. During the trial conduct, the BOIN design imposes a dose elimination (or
overdose control) rule as follows: if Pr(pj > φ | nj, yj) > 0.95 and nj ≥ 3, dose level
j and higher are eliminated from the trial, and the trial is terminated if the lowest
dose is eliminated, where Pr(pj > φ | nj, yj) is evaluated based on the posterior
distribution (2.7).
To determine the dose escalation and de-escalation boundaries (λe, λd), the
BOIN design requires the investigator(s) to specify φ1, which is the highest DLT
probability that is deemed to be underdosing such that dose escalation is required,
and φ2, which is the lowest DLT probability that is deemed to be overdosing such that
dose de-escalation is required. Liu and Yuan [19] provided general guidance to specify
φ1 and φ2, and recommended default values of φ1 = 0.6φ and φ2 = 1.4φ for general
use. When needed, the values of φ1 and φ2 can be calibrated to achieve a particular
requirement of the trial at hand. For example, if more conservative dose escalation
is required, setting φ2 = 1.2φ may be appropriate. Given φ1 and φ2 and assuming
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a non-informative prior (i.e., a priori the current dose is equally likely to be below,
equal to or above the MTD), the optimal escalation and de-escalation boundaries
(λe, λd) that minimizes the decision error of dose escalation and de-escalation arise
as,
(2.9) λe =
log
(
1− φ1
1− φ
)
log
{
φ (1− φ1)
φ1 (1− φ)
} , λd = log
(
1− φ
1− φ2
)
log
{
φ2 (1− φ)
φ (1− φ2)
} .
The following table provides the dose escalation and de-escalation boundaries (λe,
λd) for commonly used target DLT rate φ using the recommended default values
φ1 = 0.6φ and φ2 = 1.4φ.
Target DLT rate φ
Boundaries 0.15 0.2 0.25 0.3 0.35 0.4
λe 0.118 0.157 0.197 0.236 0.276 0.316
λd 0.179 0.238 0.298 0.358 0.419 0.479
For example, given the target DLT rate φ = 0.25, the corresponding escalation
boundary λe = 0.197 and the de-escalation boundary λd = 0.298, that is, escalate the
dose if the observed DLT rate at the current dose pˆj ≤ 0.197 and de-escalate the dose
if pˆj ≥ 0.298. It has been shown that (λe, λd) are the boundaries corresponding to the
Bayes factors, and thus the resulting BOIN design is optimal with desirable finite-
sample and large-sample properties, i.e., long-memory coherence and consistency
[19].
One interesting note is that the decision rule of the BOIN (with the non-
informative prior) has an appearance of the classical frequentist design and only
involves the observed DLT rate. This is common in Bayesian statistics. Many well-
established Bayesian methods (e.g., estimation for normal linear regression models)
result in the same estimators as the frequentist approach when non-informative pri-
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ors are used. Actually, the BOIN can also be derived as a frequentist design, and
its decision rule is equivalent to using the likelihood ratio test to determine dose
escalation/de-escalation [19], providing another way to proof its optimality. Having
both Bayesian and frequentist interpretations is a strength of the BOIN, making
it appealing to wider audiences. In contrast, the mTPI and keyboard designs only
have a Bayesian interpretation and require specifying priors and calculating posterior
distributions.
As the observed DLT rate pˆj is the most natural and intuitive estimate of pj
that is accessible by non-statisticians, the use of pˆj to determine the dose escalation
and de-escalation makes the BOIN design simpler and more transparent than the
mTPI/mTPI-2 and keyboard designs. It is particularly easy for clinicians and reg-
ulatory agents to assess the safety of a trial using the BOIN design, thanks to the
feature that the BOIN design guarantees de-escalating the dose when pˆj ≥ λd. For
example, given a target DLT rate φ = 0.25, we know a priori that a phase I trial using
the BOIN design guarantees de-escalating the dose if the observed DLT rate is higher
than λd = 0.298 (i.e., the default value). Accordingly, the BOIN design also allows
users to easily calibrate the design to satisfy a specific safety requirement mandated
by regulatory agents through choosing an appropriate target DLT rate φ or φ2. For
example, supposing for a phase I trial with a new compound, the regulatory agent
mandates that if the observed toxicity rate is higher than 0.25, the dose must be
de-escalated. We can easily fulfill that requirement by setting the target DLT rate
φ = 0.21, under which the BOIN automatically guarantees de-escalating the dose if
the observed toxicity rate pˆj > λd = 0.250. Such flexibility and transparency renders
the BOIN design an important advantage in practice.
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As a side note, φ1 and φ2 used in the BOIN design have different interpreta-
tions than the proper dosing interval (δ1, δ2) used in the mTPI/mTPI 2 and keyboard
designs. Specifically, φ1 and φ2 represent the DLT rates that should be regarded as
unacceptable (more precisely, underdosing and overdosing, respectively); whereas δ1
and δ2 represent the range of DLT probabilities that are acceptable. For example,
given that the target DLT probability φ = 0.25, setting φ1 = 0.15 and φ2 = 0.35
mean that the doses with the DLT rates of 0.15 and 0.35 are respectively regarded as
unacceptably underdosing and overdosing, whereas setting δ1 = 0.15 and δ2 = 0.35
means that the dose with a DLT rate between 0.15 and 0.35 is regarded as accept-
able. Thus, in general, the value of φ1 should be smaller than δ1 and the value of φ2
should be greater than δ2.
2.3 Software
The software for implementing the CRM is freely available at the MD Ander-
son Software Download Website https://biostatistics.mdanderson.org/softwaredownload/
SingleSoftware.aspx?Software_Id=81. The R code for implementing the mTPI
design is available at https://biostatistics.mdanderson.org/softwaredownload/
SingleSoftware.aspx?Software_Id=72. The software for the BOIN design is avail-
able in three forms, including a standalone graphical user interface based Windows
desktop program freely available from MD Anderson Software Download Website
https://biostatistics.mdanderson.org/softwaredownload/SingleSoftware.aspx?
Software_Id=99, Shiny online apps freely available at http://www.trialdesign.
org, and R package “BOIN” available from the CRAN. The keyboard design can be
implemented using the Shiny online app freely available at http://www.trialdesign.
org.
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2.4 Simulation study
2.4.1 Generating dose-toxicity scenarios
We generated true dose-toxicity scenarios using the pseudo-uniform algorithm
proposed by Clertant and O’Quigley [46]. Given a target DLT probability φ and J
dose levels, we generated scenarios as follows:
a. Select one of the J dose levels as the MTD with equal probabilities.
b. Sample M ∼ Beta(max{J − j, 0.5}, 1), where j denotes the selected dose level,
and set an upper bound B = φ+ (1− φ)×M for the toxicity probabilities.
c. Repeatedly sample J toxicity probabilities uniformly on [0, B] until these cor-
respond to a scenario in which dose level j is the MTD.
In these scenarios, the MTD is the dose with the DLT probability closest to the target
φ, but not necessarily equal to the target φ. Consequently, it is possible to obtain
scenarios in which all the doses have DLT probabilities below or above the target φ,
as could happen in practice. If the DLT probability at the lowest dose level is greater
than φ + 0.1, we will claim the scenario does not have MTD, and the percentage of
early termination of trials is regarded as the selection percentage of MTD. This is
one of the strength of the algorithm, which provides extensive coverage on possible
dose-toxicity scenarios that we may encounter in practice. Figure 2.2 displays 25
randomly selected scenarios with φ = 0.25 and J = 6. These exhibit a variety of
dose-toxicity curve shapes and spacings. The complete set of 10000 scenarios are
provided in Online Appendix.
2.4.2 Simulation settings
We conducted a Monto Carlo experiment to compare the performance of the
CRM, BLRM, EWOC, mTPI, BOIN, and keyboard designs, with respect to the
20
3+3 design. We considered three target DLT probabilities φ = 0.20, 0.25 and 0.30,
with 6 dose levels and a maximum sample size of 36. The starting dose level is
1. We considered 5 model-based designs: CRM (forbids dose skipping), CRM-DS
(allows dose skipping), BLRM (with the overdose control rule), BLRM-NOC (with no
overdose control rule), and EWOC. For the CRM, we used the getprior(·) function
in R to obtain the skeleton. We set the middle dose level (i.e., dose level 3 for J = 6
doses) as the prior MTD, and the halfwidth of the indifference interval equal to 0.06.
Specifically, when φ = 0.20, the skeleton is (0.032, 0.095, 0.20, 0.332, 0.470, 0.596);
when φ = 0.25, the skeleton is (0.062, 0.140, 0.25, 0.376, 0.502, 0.615); when φ = 0.30,
the skeleton is (0.095, 0.186, 0.30, 0.422, 0.540, 0.643). The dosages for BLRM and
EWOC are (12.5, 25, 50, 100, 150, 200)mg, and the reference dosage for BLRM is
d∗ = 200mg. For BLRM, following Neuenschwander et al. 2008 [9], we used the
vague bivariate normal distribution for the prior of (logα, log β), such that:
(logα, log β) ∼ N

−0.847
0.381
 ,
2.0152 0
0 1.0272


For EWOC, following Babb et al. 1998 [8], we used the non-informative priors for
γ and p1 as γ ∼ Unif(d1, 2dJ − dJ−1), p1 ∼ Unif(0, φ). We set the proper dosing
interval (δ1, δ2) = (φ − 0.05, φ + 0.05) for the mTPI, keyboard, BLRM and BLRM-
NOC designs, and φ1 = 0.6φ and φ2 = 1.4φ for BOIN, as recommended by these
designs. The 3+3 design often completes (e.g., when 2/3 or 2/6 had DLTs) before
reaching its maximum sample size. For comparability, after the 3+3 design selects
the MTD, an expansion cohort is treated at the MTD to reach the total sample
size of 36. Under each randomly generated scenario, we conducted 2000 simulated
trials. Figure shows 25 randomly selected scenarios that display various shapes of
the dose-toxicity curve. We considered cohort sizes of 3 and 1 for all designs, except
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the 3+3 design. As the results are generally similar, below we focus on the cohort
size of 3 with the target DLT probability of 0.25.
2.4.3 Performance metrics
For each of the 1000 scenarios, we calculated the following metrics:
A. Accuracy
A1. The percentage of correct selection (PCS), which is defined as the percentage
of simulated trials in which the target dose is correctly selected as the MTD.
When all the dose levels are above the MTD, PCS is defined as the percentage
of early termination of trials.
A2. The average percentage of patients who are assigned to the MTD across the
simulated trials. When all the dose levels are above the MTD, we use the
average percentage of patients not enrolled into the trial for this metric.
B. Safety
B1. The percentage of simulated trials in which a toxic dose with the true DLT
probability ≥ 33% is selected as the MTD.
B2. The average percentage of patients assigned to the toxic doses with true DLT
probability ≥ 33%.
C. Reliability
C1. The risk of overdosing, defined as the percentage of simulated trials with more
than x% of patients treated at doses above the MTD. In our simulation study,
we set x% = 50%, i.e., measuring the likelihood of a design assigning more than
half of the patients to doses above the MTD.
C2. The risk of poor allocation, defined as the percentage of simulated trials in which
fewer than 6 patients are treated at the MTD.
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C3. The risk of irrational dose assignment, defined the percentage of times that the
design fails to de-escalate the dose when 2/3 or ≥3/6 patients had DLTs at a
dose.
Metrics C1 to C3 measure the likelihood of a design demonstrating extreme
problematic behaviors (e.g., treating 50% or more patients at toxic doses, or fewer
than 6 patients at the MTD), i.e., the reliability of the design. Although these
metrics are of great practical importance, they are largely overlooked in the existing
literature. Note that these reliability metrics are not covered by other metrics. For
example, the percentage of patients overdosed (i.e., metric B2) does not cover the
risk of overdosing (i.e., metric C1). Two designs can have a similar percentage of
patients overdosed, but rather different risks of overdosing 50% of the patients (see
Results). Statistically, metric B2 measures the mean of overdosing, while metric C1
measures the tail probability of overdosing. To compare the relative performance
of the designs, we used the 3+3 design as a benchmark and report the difference
between each of the designs and the 3+3 design for each metric. For example, the
PCS for the CRM is reported as (the PCS of the CRM) (the PCS of the 3+3 design).
2.4.4 Results
A. Accuracy
Figure 2.3 A1 and A2 shows distributions of the PCS and the average per-
centage of patients treated at the MTD, respectively, for the investigational designs
relative to the 3+3 design across 1000 scenarios. As each dose-toxicity scenario gen-
erates a value of the performance metric (e.g., PCS), we obtained a total of 1000
values for each of the metrics across the 1000 scenarios. The boxplot reflects the dis-
tribution of the metric across the 1000 scenarios. In terms of the accuracy of correctly
selecting the MTD, the CRM, mTPI, BOIN and keyboard designs are comparable
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and substantially outperform the 3+3 design. The BLRM and EWOC perform the
worst, with the average PCS similar to that of the 3+3 design. The EWOC also has
the largest variation in the PCS. The poor accuracy of the BLRM can be addressed
by removing the overdose control rule: the BLRM-NOC has the highest average
PCS. However, by doing so, the resulting BLRM-NOC becomes overly aggressive
and treats a large percentage of patients above the MTD (as shown later). The
CRM-DS, which allows dose skipping, has a slightly higher PCS than the CRM, but
at the cost of increasing the risk of overdosing patients (shown later). The results
for the number of patients treated at the MTD are similar to those for the PCS. The
CRM, mTPI, BOIN and keyboard designs are generally comparable and substantially
outperform the 3+3 design. The mTPI and CRM designs allocate slightly more pa-
tients to the MTD than the BOIN and keyboard designs, but the latter two designs
are less variable, as shown by the shorter boxes in the box plot (Figure 2.3 A2).
BLRM and EWOC perform the worst, and BLRM-NOC and CRM-DS perform well,
with the highest average percentage of patients treated at the MTD. The EWOC is
the most variable method in terms of treating patients at the MTD. To illustrate the
performance of the designs under certain specific dose toxicity curves, Appendix C
shows the results under 8 representative scenarios. The results are generally similar
to Figure 2.3.
B. Safety
As shown in Figure 2.4 B1, the CRM, mTPI, BOIN and keyboard designs are
comparable in terms of the percentage of selecting a toxic dose (with DLT probability
≥ 33%) as the MTD, but CRM and mTPI are slightly more variable than the BOIN
and keyboard designs. BLRM-NOC not only has the highest chance of selecting a
toxic dose as the MTD, but also is the most variable. The BLRM and EWOC designs
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are the most conservative and least likely to select a toxic dose as the MTD. In terms
of the percentage of patients treated at a toxic dose with DLT probability ≥ 33%,
BLRM-NOC and CRM-DS stand out as the most aggressive designs, see Figure 2.4
B2. These two designs treat substantially more patients at toxic doses than the other
designs and exhibit the largest variation. On average, the CRM, mTPI, BOIN and
keyboard designs are comparable, but BOIN and keyboard show smaller variations.
The reason mTPI is more likely than the other designs to overdose at least
50% of the patients is explained previously (e.g., the UPM cannot appropriately
measure the evidence of the toxicity of a dose), and can also be seen through the
dose escalation and de-escalation rules for the three model-assisted designs reported
in Table 2.1. When the target is φ = 0.20, the default BOIN, mTPI and keyboard
designs use different thresholds for dose escalation and de-escalation. In particular,
compared to the BOIN and keyboard designs, the mTPI design is less likely to de-
escalate the dose when a high rate of toxicity is observed. For example, suppose 6
patients have been treated at the current dose, the BOIN and keyboard designs will
de-escalate the dose if 2 DLTs are observed, whereas the mTPI requires observing 3
DLTs before de-escalating the dose. Consequently, the mTPI design tends to stay
long (i.e., get stuck) at a particular dose. If that particular dose is above the MTD,
a large percentage of patients are overdosed.
C. Reliability
In terms of the risk of overdosing 50% or more of the patients (Figure 2.5
C1), the BLRM, BOIN and keyboard designs perform the best, and BLRM-NOC
performs the worst, with significantly higher (i.e., about 10% higher on average) risk.
The performance of the CRM and mTPI designs are similar and rank in between
the performances of these other designs. The EWOC has similar averaged risk of
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overdosing patients as BOIN and keyboard designs, but is much variable. We note
that CRM, mTPI, BOIN and keyboard, on average, overdose similar percentages of
patients (Figure 2.4 B2), but have different risks of overdosing 50% or more of the
patients (Figure 2.5 C1). This indicates that the risk of overdosing (50% or more
patients) and the average percentage of patients overdosed indeed measure different
aspects of a design, and it is thus important to consider both metrics when evaluating
a design. Compared to the CRM, CRM-DS had about 5% higher risk of overdosing
50% or more of the patients on average due to its aggressive dose skipping. In terms
of the risk of poor allocation (i.e., treating fewer than 6 patients at the MTD, see
Figure 2.5 C2), BLRM and EWOC perform the worst, with a significantly higher
risk than the other designs. The CRM, CRM-DS, BLRM-NOC, BOIN and keyboard
designs have comparable risks of poor allocation and keyboard design (thus mTPI-2
as well) improves the mTPI design.
In terms of the risk of irrational dose assignment (Figure 2.5 C3), the model-
assisted designs outperform the model-based designs. The model-based designs (i.e.,
the CRM, BLRM and EWOC) have 8% to 55% chance of failing to de-escalate the
dose when 2/3 or ≥3/6 patients had DLTs, whereas such irrational dose assignments
never occur in mTPI, BOIN and keyboard designs. To the best of our knowledge,
this result is new and no literature has studied such in-trial behavior of designs.
Our result discloses a disturbing, yet unsurprising, behavior of model-based designs.
The model-based designs rely on the assumed model to make the decision of dose
assignment. When the model is misspecified, the estimates can be biased and thus
irrational dose assignment arises. The model-assisted designs are free of that issue
because they do not impose any model assumption on the dose-toxicity curve. For
example, by its dose escalation/de-escalation rule, the BOIN guarantees de-escalating
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the dose if the observed DLT rate at the current dose is higher than 29.8%, given
the target DLT rate of 25%.
2.4.5 Analysis of simulation results
Our simulation results show that the CRM, BOIN and keyboard designs have
comparable, good operating characteristics, especially in terms of PCS and the risk of
overdosing a large percentage of patients. However, when we examine each scenario
individually, we find that in certain scenarios the CRM has much higher PCS than
the BOIN and keyboard designs, while in other scenarios the reverse is true. In this
section we aim to characterize the scenarios in which the CRM outperforms the BOIN
design, and vice versa. Because the keyboard design has very similar performance as
the BOIN, in what follows, we focus on the CRM and BOIN. In the trial conduct of
CRM, the parameter α in (2.1) is continuously updated to reflect the accruing data.
We hypothesized that if there exists an α0 such that the fitted toxicity probabilities
pi(α0) = (a
exp(α0)
1 , . . . , a
exp(α0)
J ) from the power model are close to the true toxicity
probabilities (i.e., if the power model provides a good fit to the true dose-toxicity
curve), then the CRM will outperform the BOIN design, and vice versa. To verify
our hypothesis, first, given a specific dose-toxicity scenario with true toxicity rates
(p∗1, · · · , p∗J), we defined a goodness-of-fit (GOF) index for the toxicity probabilities
as follows,
GOF = min
α
√√√√ J∑
j=1
(
a
exp(α)
j − p∗j
)2
.
The GOF index summaries the difference or distance between the best-fitted CRM
model and the true dose-toxicity curve, in terms of the mean square error. A smaller
value indicates that the CRM model can provide a better fit to the true dose-toxicity
curve. The value of GOF is determined through the grid search over α. Second, we
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selected the scenarios in which CRM had a PCS that was at least 10% higher than
BOIN, and the scenarios in which BOIN has a PCS that was at least 10% higher
than CRM. Third, using K-means clustering [48], we partitioned these two sets of
scenarios into 3 clusters. Figure 2.6 shows the median scenario in each cluster, as well
as the best model-fitted curve (dotted lines). Figure 2.6 shows that, compared to the
dose-toxicity curves that favor the BOIN design, the dose-toxicity curves that favor
the CRM are closer to the corresponding best model-fitted curve. The first three
scenarios—in which the CRM has better PCS than BOIN—correspond to smaller
GOF indexes than the latter three scenarios—in which BOIN has better PCS than
the CRM.
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Figure 2.1: Decision of dose escalation and de-escalation under the CRM/EWOC/BLRM, mTPI,
BOIN and keyboard designs. (a) CRM/EWOC/BLRM uses the estimated dose-toxicity curve that
is continuously updated based on accumulative data; curve labeled initial is the initial estimate
of the dose-toxicity curve before the first cohort is treated; curve labels “0/3”, “1/3” and “2/3”
represent the updated estimate of the dose-toxicity curve when 0/3 and 1/3 and 2/3 patients had
DLT, respectively. (b) mTPI calculates and compares the UPMs of the underdosing, proper dosing
and overdosing intervals. (c) BOIN compares the observed DLT rate at the current dose with the
prespecified dose escalation boundary λe and de-escalation boundary λd. (d) The keyboard design
forms a series of equal-width keys and bases the decision on the position of the strong key with
respect to the target key.
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Figure 2.2: Relation between dose level and toxicity. (a) 25 randomly selected dose-toxicity curves
with 6 picked curves showing different shapes; (b) distribution of the DLT probabilities by dose
level from the 1000 scenarios.
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Figure 2.3: Comparison of accuracy metrics for the 8 designs with respect to the 3+3 design. A1.
Percentage of correct selection of the MTD; A2. Percentage of patients treated at the MTD; A
larger value indicates better performance; positive value means that the design outperforms the
3+3 design.
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Figure 2.4: Comparison of safety metrics for the 8 designs with respect to the 3+3 design. B1.
Percentage of selecting doses with DLT probability ≥ 33% as the MTD; B2. Percentage of pa-
tients treated at doses with DLT probability ≥ 33%; A smaller value indicates better performance;
negative value means that the design outperforms the 3+3 design.
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Figure 2.5: Comparison of reliability metrics for the 8 designs with respect to the 3+3 design. C1.
Risk of overdosing 50% or more patients; C2. Risk of treating < 6 patients at the MTD; C3. Risk
of irrational dose assignment. A smaller value indicates better performance; negative value means
that the design outperforms the 3+3 design.
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Table 2.1: Escalation and De-escalation rules for the mTPI, BOIN and Keyboard designs under
their default settings for a target toxicity rate of φ = 0.2.
Number of patients treated at the current dose
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
mTPI Design
Escalate if number of DLTs ≤ 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1
De-escalate if number of DLTs ≥ 1 2 2 2 3 3 4 4 4 5 5 5 5 6 6 6
BOIN Design
Escalate if number of DLTs ≤ 0 0 0 0 0 0 1 1 1 1 1 1 2 2 2 2
De-escalate if number of DLTs ≥ 1 1 1 1 2 2 2 2 3 3 3 3 4 4 4 4
Keyboard Design
Escalate if number of DLTs ≤ 0 0 0 0 0 0 0 1 1 1 1 1 1 1 2 2
De-escalate if number of DLTs ≥ 1 1 1 1 2 2 2 2 3 3 3 3 4 4 4 4
1 2 3 4 5 6
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Figure 2.6: Medians of clustered dose-toxicity curves favoring CRM and BOIN designs. Dotted
lines are the best model-fitted curves from the CRM design.
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CHAPTER 3
BOP2: Bayesian Optimal Design for Phase II Clinical Trials
with Simple and Complex Endpoints
3.1 Introduction
This chapter is based on “BOP2: Bayesian optimal design for phase II clinical
trials with simple and complex endpoints”, published in Statistics in Medicine (2017)
[49] coauthored with Jack J. Lee and Ying Yuan. Permission from the journal has
been granted for use in conjunction with the dissertation.
Traditionally, phase II clinical oncology trials have focused on binary efficacy
endpoints, e.g., tumor response, but they have become much more complicated with
the advent of novel molecular targeted agents and immunotherapy. The endpoints
for such treatments may be ordinal or multivariate, and the investigators are of-
ten interested in simultaneously monitoring multiple types of events in the trial, as
illustrated by the following trial examples.
Example 1. Binary efficacy endpoint The aim of a phase II trial is to
evaluate the efficacy of pembrolizumab in patients with advanced small bowel ade-
nocarcinomas. The primary endpoint is the ORR, defined using RECIST, version
1.1. The treatment is regarded as futile if the ORR ≤ 20% and promising if the ORR
≥ 40%. This example is used to illustrate the standard case with a binary efficacy
endpoint.
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Example 2. Nested efficacy endpoints The aim of a phase II clinical trial is
to assess the efficacy of nivolumab in patients with Hodgkin’s lymphoma who have
not experienced a successful outcome following an autologous stem cell transplant.
The revised International Working Group Criteria for Malignant Lymphoma [50] is
used to define the efficacy of treatments for lymphoma, categorized as one of four
levels of decreasing desirability: complete remission (CR), defined as the disappear-
ance of all evidence of disease; partial remission (PR), defined as the regression of
measurable disease and no new sites; stable disease (SD), defined as failure to attain
CR, PR or progressive disease (PD); and PD, defined as evidence of any new lesion
or an increase in lesion volume ≥ 50% from the nadir of previously involved sites.
In this trial, although both CR and PR are regarded as favorable responses, CR
is substantially more desirable. The treatment is regarded as promising if (1) the
probability of achieving CR or PR ≥ 30% or (2) the probability of achieving CR ≥
15%, where the endpoint of the second condition is a part of the endpoints of the
first condition.
Example 3. Co-primary efficacy endpoints The primary objective of a
phase II trial is to evaluate the efficacy of trebananib administered at 15 mg/kg IV
per week in patients with persistent or recurrent carcinoma of the endometrium [51].
The trial has two co-primary efficacy endpoints: the objective response rate (ORR)
and the event-free survival at 6 months (EFS6). The objective response (OR) is
defined using the Response Evaluation Criteria in Solid Tumors (RECIST), version
1.1 [52]. The event-free survival is defined as the length of time from the initiation
of the treatment to disease progression, death, or beginning a subsequent therapy.
The null hypothesis is that the ORR ≤ 10% and EFS6 ≤ 20%. In other words, the
treatment is regarded as futile only if the ORR ≤ 10% and EFS6 ≤ 20%. Clinically
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significant differences are defined as a 20% increase in PFS6, or a 15% increase in
ORR.
Example 4. Jointly monitoring efficacy and toxicity In a phase II clini-
cal trial, patients with recurrent indolent non-follicular lymphoma are treated with
lenalidomide in combination with rituximab [53]. Lenalidomide is administered at
20 mg/day for days 1-21, and rituximab is administered at 375 mg/m2 once on day
14 of every 28 days. The primary efficacy endpoint is the ORR as defined using the
1999 Cheson criteria. Because of large uncertainty regarding the safety of the com-
bination treatment, the trial also monitors dose-limiting toxicity, defined according
to the National Cancer Institute Common Terminology Criteria for Adverse Events.
The lowest acceptable ORR is 45% and the highest acceptable toxicity rate is 30%.
We propose a flexible Bayesian optimal phase II (BOP2) design that is capable
of handling the aforementioned trials in a unified framework. We use a Dirichlet-
multinomial model to embrace different types of endpoints. At each interim, the
go/no-go decision is made by evaluating the posterior probabilities of the events of
interest. The BOP2 design explicitly controls the type I error rate and is optimal
in the sense that it optimizes power or minimizes the expected sample size under
the null hypothesis. Thall and colleagues [54, 55, 56] proposed Bayesian sequen-
tial monitoring designs for multiple response outcomes (e.g., toxicity and efficacy).
Compared to these designs, the advantage of the proposed BOP2 design includes (1)
offering a more flexible framework to monitor multiple events simultaneously, includ-
ing nested or co-primary endpoints; (2) explicitly controlling the type I error rate,
thereby bridging the gap between Bayesian designs and frequentist designs and also
rendering the proposed Bayesian design more accessible to a wide range of users and
regulatory agencies; and (3) allowing the cutoffs of the stopping rule to vary with
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the interim sample size, which improves the power of the design, as demonstrated in
our simulation studies.
3.2 Methods
3.2.1 Probability model
Although the endpoints of the aforementioned trials take different forms, they
can be unified and represented by a random variable Y that follows a multinomial
distribution,
Y ∼Multinom(θ1, . . . , θK),
where θk = Pr(Y = k) is the probability that Y belongs to the kth category, k =
1, · · · , K. The K categories can be the actual levels of a single endpoint or the
combinational levels of multiple categorical endpoints. For example, in trial example
2, Y is the ordinal outcome, with Y = 1, 2, 3 and 4 denoting CR, PR, SD and PD,
respectively. In trial example 3, Y is a multinomial variable with four categories
where 1 = (OR, EFS6), 2 = (OR, no EFS6), 3 = (no OR, EFS6) and 4 = (no
OR, no EFS6). Similarly, in trial example 4, Y is a multinomial variable with four
categories: 1 = (toxicity, OR), 2 = (no toxicity, OR), 3 = (toxicity, no OR) and
4 = (no toxicity, no OR). Trial example 1 can be viewed as a special case of trial
example 2 by ignoring EFS6, where Y has only two categories (i.e., OR or no OR).
In this case, the multinomial distribution degenerates to a binomial distribution.
Suppose that at an interim time, a total of n patients have been enrolled
into the trial and their endpoints have been fully evaluated. Let Dn = (x1, · · · , xK)
denote the interim data, and xk denote the number of patients with Y = k, where∑K
k=1 xk = n. Assuming that θ = (θ1, . . . , θK)
T follows a Dirichlet prior,
(θ1, ..., θK) ∼ Dir(a1, . . . , aK),
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where a1, . . . , aK are hyperparameters, the posterior distribution of θ is given by
θ|Dn ∼ Dir(a1 + x1, · · · , aK + xK).
We set
∑K
k=1 ak = 1 such that the prior is vague and equivalent to a prior sample
size of 1. In the special case that Y is a binary outcome (e.g., trial example 1), this
Dirichlet-multinomial model becomes a standard beta-binomial model.
3.2.2 Trial design
Let N denote the maximum sample size of the trial. The proposed BOP2
design consists of R interim looks, which occur when the number of enrolled patients
reaches n1, · · · , nR, and a final look when all N patients are enrolled. At each of these
looks, the go/no-go decision is made based on the accumulating data, as described
below. In other words, patients are enrolled in R + 1 cohorts of size n1, n2 − n1, ...,
nR − nR−1 and N − nR, respectively, and the go/no-go decision is made after each
cohort is enrolled. When R = N − 1, we obtain a full sequential design in which
the go/no-go decision is continuously assessed after each patient. For notational
brevity, we suppress the subscript of the interim sample size when this does not
cause confusion.
Let C(n) denote a probability cutoff, which is a function of the interim sample
size n. Under the proposed design, the go/no-go decision at each interim is made
based on the posterior probability of the events of interest. Specifically, for the four
trial examples, the interim stopping rule is described as follows. At an interim look,
terminate the trial if
(Example 1): Pr(θ1 ≤ 0.2|Dn) > C(n)
(Example 2): Pr(θ1 ≤ 0.15|Dn) > C(n) and Pr(θ1+θ2 ≤ 0.3|Dn) > C(n)
(Example 3): Pr(θ1 + θ2 ≤ 0.1|Dn) > C(n) and Pr(θ1 + θ3 ≤ 0.2|Dn) >
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C(n)
(Example 4): Pr(θ1 + θ2 ≤ 0.45|Dn) > C(n) or Pr(θ1 + θ3 > 0.3|Dn) >
C(n).
Unlike most existing Bayesian designs [33, 54, 55], which assume a constant
cutoff, here we allow the cutoff C(n) to be a function of the interim sample size n. As
we show later, such modification is important and substantially improves the power of
the design. Although these stopping rules have different clinical interpretations, the
go/no-go decisions are all based on the evaluation of a set of the posterior probabilities
of the linear combination of the model parameters θ = (θ1, · · · , θK)T , for example,
(3.1) Pr(bθ ≤ φ|Dn) > C(n),
where b is a design vector with elements of 0 and 1, and φ is a prespecified threshold.
For example, in trial example 2, the stopping rule involves the evaluation of two
posterior probabilities, with b = (1, 0, 0, 0) and φ = 0.15, and b = (1, 1, 0, 0) and
φ = 0.3, respectively; and in trial example 3, the stopping rule involves the evaluation
of two posterior probabilities, with b = (1, 1, 0, 0) and φ = 0.1, and b = (1, 0, 1, 0)
and φ = 0.2, respectively.
The evaluation of the posterior probability in (3.1) is facilitated by the fol-
lowing property of the Dirichlet distribution.
Property 1. Given θ ∼ Dir(a1 + x1, · · · , aK + xk) and a design vector b =
(b1, · · · , bK) with elements of 0 and 1, bθ follows a Beta distributionBeta(
∑K
k=1 bk(ak+
xk),
∑K
k=1(1− bk)(ak + xk)).
As a result, Pr(bθ ≤ φ|Dn) can be easily evaluated as
Pr(bθ ≤ φ|Dn) = B
(
φ;
K∑
k=1
bk(ak + xk),
K∑
k=1
(1− bk)(ak + xk)
)
,
39
where B(φ; ζ, ξ) is the cumulative distribution function of a Beta distribution with
parameters ζ and ξ, evaluated at value φ. This property of Pr(bθ ≤ φ|Dn) leads to
the following result.
Lemma 1. Pr(bθ ≤ φ|Dn) is a monotonic function of
∑K
k=1 bkxk.
The monotonicity of Pr(bθ ≤ φ|Dn) is important in practice because it allows us to
enumerate the stopping boundary prior to the onset of the trial, similar to Simon’s
two-stage design, as shown in Table 3.1. For example, the row “Example 2” shows
the interim stopping boundary in terms of the number of patients with CR and
CR/PR for our trial example 2. During trial conduct, we do not need to carry out
any complicated calculations; rather, we just need to count the number of relevant
events and make the go/no-go decision based on whether that count exceeds the
boundary. For example, after 20 patients are treated, if the number of CR responses
is ≤ 3 and the number of CR/PR responses is ≤ 5, we terminate the trial early. This
property makes the BOP2 design very easy to implement in practice.
3.2.3 Optimizing design parameters
Suppose that appropriate null hypothesis H0 and alternative hypothesis H1
have been chosen to reflect clinical interests, where H0 specifies the value of θ,
under which the treatment is deemed as futile; and H1 specifies the value of θ,
under which the treatment is deemed as promising. For example, for trial example
2, H0 : θ1 = 0.15 and θ1 + θ2 = 0.3, and a reasonable alternative hypothesis is
H1 : θ1 = 0.25 and θ1 + θ2 = 0.5. With complicated endpoints (e.g., two co-primary
endpoints), the specification of H1 is less straightforward and should be determined
through consultation with clinicians to reflect a desirable outcome that is feasible
in practice. We reject H0 and claim that the treatment is promising if the stopping
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boundaries are never crossed throughout the trial (including at the end of the trial).
The type I error rate and statistical power are defined as the probability of rejecting
H0 under H0 and H1, respectively.
The operating characteristics of the BOP2 design rely on the specification of
the probability cutoff C(n). Although any reasonably flexible monotonically decreas-
ing function may be used, one particular function of C(n) that is simple and yields
good operating characteristics is the following two-parameter power function
(3.2) C(n) = 1− λ(n/N)γ,
where λ and γ are tuning parameters. We require that γ > 0 such that C(n)
is monotonically decreasing with n/N , the fraction of the accumulated information.
The rationale is that at the beginning of the trial, data are sparse and a more relaxed
stopping rule with a larger value of C(n) may be preferred to avoid terminating the
trial accidentally. When the trial proceeds and information accumulates, we have
less uncertainty regarding the endpoint of interest and thus it is desirable to have a
more stringent stopping rule with a smaller value of C(n) to terminate the trial for
an inefficacious treatment. The remaining questions are how to choose the tuning
parameters λ, γ and sometimes N in (3.2) to optimize the performance of the design
according to a certain criterion.
We first consider how to choose the tuning parameters λ and γ when sample
size N is fixed, for example, due to a fixed budget or limited accrual. Our strategy
is to choose λ and γ to maximize the power of the BOP2 design, while controlling
the type I error rate at a certain prespecified level. This can be done as follows:
Step 1: Elicit from clinicians H0 and H1, and the desirable type I error rate.
Step 2: Find the values of (λ, γ) that yield the desirable type I error rate, which can
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be done through a grid search.
Step 3: Among the set of (λ, γ) identified in Step 2, select the one that yields the
maximum statistical power as the optimal design parameters.
Although the BOP2 design is a Bayesian design, it is still essential to ensure that
the design has desirable frequentist operating characteristics (e.g., type I rate and
power). In general, a good Bayesian design should demonstrate reasonable frequen-
tist operating characteristics [57]. Explicitly controlling the type I error rate is an
important feature that distinguishes the BOP2 design from most existing Bayesian
phase II designs. This feature bridges the gap between Bayesian designs and fre-
quentist designs, making the BOP design accessible to a wide range of users and
regulatory agencies.
An alternative optimization strategy is to choose λ and γ, as well as sample
size N , to minimize the expected sample size under H0, i.e., E(N |H0), given prespec-
ified type I and II error rates. This optimization criteria was used in Simon’s optimal
design. In this approach, N is not fixed, but a design parameter to be optimized.
The procedure to determine the values of (λ, γ, N) that minimize E(N |H0) can be
described as follows:
Step 1: Elicit from clinicians H0 and H1, and desirable type I and II error rates.
Step 2: Find the values of (N, λ, γ) that yield the desirable type I and II error rates,
which can be done through a grid search.
Step 3: Among the set of (N, λ, γ) identified in Step 2, select the one that yields the
smallest E(N |H0) as the optimal design parameters.
In Step 2, we have two constraints (i.e., type I and II error rates), but need to
determine the values of three unknown parameters (N, λ, γ). Thus, in principle, there
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are an infinite number of possible solutions. We circumvent this issue by restricting
the value of N within the range of (Nmin, Nmax), where Nmax is the maximum sample
size that we can afford in practice, which is often determined by budget, accrual rate
or other practical factors. Nmin is the minimal sample size for the trial, which has
little impact on the operating characteristics of the design as long as it is reasonably
small, such as Nmin = 10. Given a specific value of N , we can uniquely determine the
values of λ and γ based on the two constraints through a grid search. One potential
limitation of this optimization strategy is that we do not have a direct control on
sample size N , and the value of N that minimizes E(N |H0) may be excessively large
for practical use in some cases. When this is a concern, the minimax criterion can
be used to optimize the design. That is, instead of minimizing E(N |H0), we choose
(λ, γ, N) to minimize the maximum sample size.
3.3 Web application
To facilitate the use of the BOP2 design, we develop an easy-to-use web appli-
cation using Shiny. Figure 3.2 shows the graphical user interface of the application.
After users input their design parameters (e.g., the maximum sample size, cohort
size, desirable type I and II errors and the type of endpoints to be monitored), the
web application generates the operating characteristics and stopping boundary of
the BOP2 design that can be included in the trial protocol. As described previ-
ously, similar to Simon’s two-stage design, one important advantage of the BOP2
design is that its stopping boundary can be enumerated and included in the trial
protocol prior to the onset of the trial. When conducting the trial, we simply count
the number of relevant events and make the go/no-go decision based on whether
that count exceeds the boundary. Our web application will be freely available at
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http://www.trialdesign.org and also the author’s website.
3.4 Simulation study
In the following simulation studies, we controlled the type I error rate at 0.1
for all designs. Due to the discrete nature of the observed data, a cutoff that yields
a type I error rate of exactly 0.1 does not usually exist. In these cases, we chose the
cutoff that yielded a type I error rate closest to and not higher than the nominal
value. For clarity, in what follows, we focus on the BOP2 design that maximizes
power. Interim analyses were carried out after the first 10 patients were treated,
then after every 5 additional patients were treated, with the maximum sample size
N = 40. The results of the BOP2 design that minimizes E(N |H0) are similar and
provided in the Appendix.
To evaluate the performance of the designs, we considered the following three
metrics. (1) The percentage of rejecting the null hypothesis (PRN) is defined as the
percentage of the simulated trials in which H0 is rejected. The PRN is the type I
error rate (or power) when H0 is (or is not) true. The PRN can be also explained as
the percentage of claiming that the new treatment is effective. (2) The percentage
of early termination (PET) is defined as the percentage of trials that are terminated
early. (3) The actual sample size is defined as the average sample size actually used
in 10,000 simulated trials.
3.4.1 Binary efficacy endpoint
We first evaluated the operating characteristics of the BOP2 design under
the conventional setting with a simple binary efficacy outcome (i.e., OR/no OR), as
illustrated by trial example 1. We selected four pairs of H0 and H1, and compared
the BOP2 design to the Bayesian design proposed by Thall and Simon [33], denoted
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as the TS design. In the first scenario, for example, the TS design employed a beta-
binomial model and terminated the trial if Pr(θ1 < 0.2|Dn) > C, where C is a fixed
cutoff. We calibrated the value of C to control the type I error rate of the TS design
at 0.1, which matches that of the BOP2 design. Table 3.1 provides the stopping
boundaries of the BOP2 design in terms of the observed number of patients who had
responses, which were used to make the go/no-go decision at each interim look for
scenario 1 in Table 3.2.
Table 3.2 shows the performance of the two designs under four different pairs
of H0 and H1 on the ORR, represented as scenarios 1-4. In general, the BOP2 design
yielded substantially higher power than the TS design. For example, in scenario 1,
where the null ORR is 0.2 and the alternative ORR is 0.4, when the true ORR is
0.4, the power of the BOP2 design is 88.3%, whereas the power of the TS design is
only 76.4%. In addition, compared to the TS design, the BOP2 design had a lower
risk of incorrectly terminating the trial when the treatment is actually effective. For
example, when the true ORR is 0.4, the TS design incorrectly terminated the trial
23.5% of the time, while the BOP2 design incorrectly terminated the trial 11.4%
of the time. Under the null hypothesis, the TS design had a higher probability
of terminating the trial than the BOP2 design. Because the TS design had a high
tendency of terminating the trial, it has smaller (actual) sample sizes than the BOP2
design. Due to the discrete nature of the observed data and different ways of defining
the cutoff (i.e., the TS design uses a fixed cutoff C and the BOP2 design uses an
adaptive cutoff C(n)), in some cases, it is not possible to exactly match the type I
error rate of two designs to 0.1. That is why in some scenarios (e.g., scenario 1), the
type I error of the TS design is slightly lower than the BOP2 design, but slightly
higher in other scenarios (e.g., scenario 2).
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Figure 3.1 contrasts the stopping boundaries of the two designs under scenario
1 in Table 3.2. At each interim look, the trial is terminated if the number of observed
responses does not exceed the line in the plot. In the early stages of the trial,
the BOP2 design has lower boundaries because of the relaxed stopping rules. At
later stages, the BOP2 design applies more stringent stopping rules to yield higher
boundaries than the TS design. Similar patterns are observed in the boundary plots
for other scenarios in Table 3.2.
3.4.2 Nested efficacy endpoints
Table 3.3 shows the simulation results for the ordinal endpoint under the
setting of trial example 2, and Table 3.1 shows the corresponding boundaries. Interim
monitoring started after the first 10 patients were enrolled, and then was performed
after every 5 patients was enrolled. The null hypothesis is scenario 1, i.e., H0 :
Pr(CR) = 0.15 and Pr(CR/PR) = 0.3, and the alternative hypothesis is scenario 7,
i.e., H1: Pr(CR) = 0.25 and Pr(CR/PR) = 0.5. We compared the BOP2 design with
the TS design, which regards CR/PR as response and SD/PD as nonresponse, as is
often done in practice. Thus, the TS design employed the beta-binomial model and
terminated the trial if Pr(θ1 < 0.3|Dn) > C, where C is a fixed cutoff. We calibrated
the value of C to control the type I error rate of the TS design at 0.1.
As shown in Table 3.3, the BOP2 design generally has more power than the
TS design. For example, in scenario 7, where Pr(CR) = 0.25 and Pr(CR/PR) = 0.5,
the power of the BOP2 design is 85.5%, whereas that of the TS design is 74.2%.
Comparing the first two scenarios, we observe that the BOP2 design can increase
the PRN from 8.7% to 24.2% because the true CR rate increases from 0.15 to 0.20.
This exactly fulfills our expectation of the BOP2 design, which can monitor nested
endpoints simultaneously. In contrast, the TS design could not distinguish these
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two scenarios because the CR/PR rates are both 0.30. In addition, the TS design
tended to incorrectly terminate the trial more frequently than the BOP2 design
when the treatment actually was effective. For example, in scenario 7, the TS design
terminated the trial early 25.7% of the time, whereas the BOP2 design terminated
the trial early 9.9% of the time. Again, due to a high tendency of terminating the
trial early, the actual sample size of the TS design is smaller than that of the BOP2
design.
3.4.3 Co-primary efficacy endpoints
Table 3.4 shows the simulation results under the setting of trial example 3,
with two co-primary efficacy endpoints (i.e., ORR and EFS6), and Table 3.1 shows
the corresponding boundaries. The H0 and H1 are scenarios 1 and 7, respectively.
We compared the BOP2 design to a Bayesian design inspired by the method of Thall,
Simon and Estey [54], and denoted the latter as the TSE design. For fair comparison,
the TSE design used the same model and stopping rule as the BOP2 design, except
that a fixed cutoff C was used in the stopping rule, as suggested by Thall, Simon
and Estey [54]. The results are generally similar to those described previously. That
is, the BOP2 design yielded higher power and was less likely to incorrectly terminate
the trial than the TSE design.
3.4.4 Efficacy and toxicity endpoints
Table 3.5 shows the simulation results under the setting of trial example 4,
where we simultaneously monitored efficacy and toxicity. Scenarios 1 and 7 show H0
and H1, respectively. We compared the BOP2 design with the TSE design, which
used the same model and stopping rule as the BOP2 design, except that a fixed cutoff
C was used in the stopping rule. Again, given the same type I error rate (i.e., PRN
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in scenario 1), the BOP2 design outperformed the fixed-cutoff design with higher
power and smaller risk of incorrectly terminating the trial.
The corresponding boundaries are shown in Table 3.1. The use of stopping
boundaries in this case is slightly different from that in the previous cases. For
example, after 30 patients are treated, the BOP2 design terminates the trial if either
the number of responses is ≤ 13 or the number of toxicities is ≥ 10.
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Table 3.1: Stopping boundaries of the BOP2 design for four trial examples. Maximum sample size
is 40.
Number of patients treated
Trial Stop the trial if 10 15 20 25 30 35 40
Example 1 # of ORR ≤ 1 2 4 5 7 9 10
Example 2 and
# of CR ≤ 0 1 3 4 5 7 9
# of CR/PR ≤ 2 3 5 8 10 13 16
Example 3 and
# of ORR ≤ 0 1 2 3 4 5 7
# of EFS ≤ 1 2 4 5 7 9 12
Example 4 or
# of Responses ≤ 2 5 7 10 13 16 19
# of Toxicities ≥ 5 6 8 9 10 11 12
Table 3.2: Percentage of rejecting the null (PRN), percentage of early termination (PET), and
actual sample size under the BOP2 design and TS design (Thall and Simon, 1994) with a binary
endpoint as described in trial example 1.
Response rate PRN(%) PET(%) Sample size
Scenario (ORR) BOP2 TS BOP2 TS BOP2 TS
1 0.20§ 9.6 9.4 88.8 89.8 20.2 15.3
0.30 55.2 42.6 46.2 56.7 31.0 24.9
0.40† 88.3 76.4 11.4 23.5 37.6 33.6
0.50 98.2 93.3 1.8 6.7 39.5 38.1
2 0.30§ 9.4 10.0 82.8 89.5 22.2 15.6
0.40 48.2 40.3 41.4 59.4 31.9 24.3
0.50† 86.7 74.0 10.3 25.9 37.7 32.9
0.60 98.9 92.7 1.8 7.3 39.5 37.9
3 0.40§ 10.0 10.0 84.3 89.0 21.6 15.4
0.50 47.5 38.3 46.0 61.1 31.0 23.5
0.60† 86.3 72.1 11.9 27.9 37.5 32.4
0.70 98.2 92.5 1.7 7.5 39.6 37.9
4 0.50§ 7.2 7.2 79.5 92.4 24.7 13.4
0.60 43.0 29.6 36.3 70.2 33.9 20.0
0.70† 87.3 61.9 6.4 38.1 38.9 28.9
0.80 99.6 87.6 0.2 12.4 40.0 36.3
§: null hypothesis; †: alternative hypothesis.
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Table 3.3: Percentage of rejecting the null (PRN), percentage of early termination (PET), and the
actual sample size under the BOP2 design and TS design (Thall and Simon, 1994) with nested
endpoints as described in trial example 2.
PRN(%) PET(%) Sample size
Scenario θ (CR, CR/PR) BOP2 TS BOP2 TS BOP2 TS
1 (0.15,0.15,0.30,0.40)§ (0.15, 0.30) 8.7 9.9 82.1 89.6 25.4 15.7
2 (0.20,0.10,0.30,0.40) (0.20, 0.30) 24.2 9.6 63.8 89.9 29.0 15.6
3 (0.20,0.15,0.30,0.35) (0.20, 0.35) 30.6 22.9 56.3 76.6 31.0 19.7
4 (0.20,0.20,0.30,0.30) (0.20, 0.40) 45.9 40.7 41.0 59.2 33.8 24.4
5 (0.20,0.25,0.30,0.25) (0.20, 0.45) 66.3 58.7 24.1 41.2 36.4 29.0
6 (0.25,0.20,0.30,0.25) (0.25, 0.45) 72.3 59.0 19.3 40.9 37.1 29.1
7 (0.25,0.25,0.25,0.25)† (0.25, 0.50) 85.5 74.2 9.9 25.7 38.5 33.0
8 (0.30,0.25,0.25,0.20) (0.30, 0.55) 95.7 85.2 3.0 14.8 39.5 35.9
§: null hypothesis; †: alternative hypothesis.
Table 3.4: Percentage of rejecting the null (PRN), percentage of early termination (PET), and the
actual sample size under the BOP2 design and TSE design (Thall, Simon and Estey, 1995) with
two co-primary efficacy endpoints as described in trial example 3.
PRN(%) PET(%) Sample size
Scenario θ (ORR, EFS) BOP2 TSE BOP2 TSE BOP2 TSE
1 (0.05,0.05,0.15,0.75)§ (0.10, 0.20) 7.2 7.3 80.9 92.3 24.5 13.7
2 (0.05,0.10,0.15,0.70) (0.15, 0.20) 23.9 17.4 58.9 82.3 29.7 16.5
3 (0.10,0.10,0.15,0.65) (0.20, 0.25) 56.5 37.1 29.7 62.8 35.0 22.0
4 (0.10,0.15,0.15,0.60) (0.25, 0.25) 79.7 53.0 12.8 47.0 37.8 26.3
5 (0.10,0.15,0.20,0.55) (0.25, 0.30) 85.9 60.7 7.6 39.3 38.7 28.5
6 (0.15,0.15,0.10,0.60) (0.30, 0.25) 91.3 64.4 6.6 35.6 38.6 29.5
7 (0.15,0.15,0.20,0.50)† (0.30, 0.35) 96.1 75.5 2.4 24.5 39.5 32.8
8 (0.15,0.15,0.25,0.45) (0.30, 0.40) 98.5 82.6 0.8 17.4 39.8 34.8
§: null hypothesis; †: alternative hypothesis.
Table 3.5: Percentage of rejecting the null (PRN), percentage of early termination (PET), and the
actual sample size under the BOP2 design and the TSE design (Thall, Simon and Estey, 1995) with
jointly monitoring efficacy and toxicity endpoints as described in trial example 4.
PRN(%) PET(%) Sample size
Scenario θ (Eff, Tox) BOP2 TSE BOP2 TSE BOP2 TSE
1 (0.15,0.30,0.15,0.40)§ (0.45, 0.30) 9.3 9.2 85.3 89.6 22.1 15.2
2 (0.20,0.30,0.15,0.35) (0.50, 0.35) 7.5 7.1 88.5 91.3 20.6 14.6
3 (0.10,0.30,0.15,0.45) (0.40, 0.25) 6.7 7.5 88.7 91.4 21.2 14.7
4 (0.15,0.35,0.10,0.40) (0.50, 0.25) 30.7 25.5 61.7 73.3 28.2 20.1
5 (0.15,0.35,0.05,0.45) (0.50, 0.20) 41.0 33.8 51.2 65.3 30.7 22.4
6 (0.15,0.40,0.05,0.40) (0.55, 0.20) 60.8 48.6 33.5 50.8 33.9 26.1
7 (0.18,0.42,0.02,0.38)† (0.60, 0.20) 74.6 59.8 22.0 39.7 36.0 29.1
8 (0.15,0.50,0.05,0.30) (0.65, 0.20) 82.6 69.4 15.1 30.3 37.0 31.7
§: null hypothesis; †: alternative hypothesis.
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Figure 3.1: Stopping boundaries of BOP2 design and TS design for the binary efficacy endpoint
(i.e., trial example 1) under scenario 1 shown in Table 3.2. The maximum sample sizes of the two
designs are 40.
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Figure 3.2: Web application for the BOP2 design
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CHAPTER 4
Bayesian Optimal Phase II Design for Cancer
Immunotherapy
4.1 Introduction
The objective response rate is a short-term endpoint in phase II clinical trials,
which can be assessed usually in the first cycle of treatment. The long-term survival
and durable response rates are also desirable endpoints, which indicate the patients
being cured. We propose an optimal phase II clinical trial design to simultaneously
model the objective response rate (ORR) and the cure rate (e.g., long-term survival
and durable tumor response). Consider the trial example 2 described in section 3.1.
Suppose the new treatment is expected to achieve more than 10% in durable clinical
response rate, the interim decision should be based on the rule: the treatment is
regarded as promising if (1) the probability of achieving CR or PR rate ≥ 30%, or
(2) the probability of achieving CR rate ≥ 15%, or (3) the probability of achieving
cure rate ≥ 10%. In order to model the cure rate among the patients population,
we use the mixture cure rate model proposed by Berkson and Gage (1952) since it
could capture the information of both “cured” and “non-cured” subsets at the same
time [58]. Following the BOP2 design, we use the non-constant posterior probability
cutoff to make interim decision and optimize the design parameters while controlling
the type I error rate. Therefore the proposed design is an extension to the BOP2
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design, which we call BOP2-C design.
4.2 Methods
4.2.1 Probability model
In the first cycle of treatment, we define Y as the ordinal outcome, with
Y = 1, 2, 3 and 4 denoting CR, PR, SD and PD, respectively. Thus Y follows the
multinomial distribution such that
Y ∼Multinom(pi1, pi2, pi3, pi4),
where pik = Pr(Y = k), k = 1, 2, 3, 4, and
∑4
k=1 pik = 1. Suppose that at an interim
time, a total of n patients have been enrolled into the trial and their responses
have been fully observed. Let Dn = (n1, n2, n3, n4) denote the interim data, and nk
denote the number of patients with Y = k, where
∑4
k=1 nk = n. Assuming that
pi = (pi1, pi2, pi3, pi4)
T follows a Dirichlet prior,
(pi1, pi2, pi3, pi4) ∼ Dir(a1, a2, a3, a4),
where a1, a2, a3, a4 are hyperparameters, the posterior distribution of pi is given by
pi|Dn ∼ Dir(a1 + n1, a2 + n3, a3 + n3, a4 + n4).
Let θ denote the cure rate in patients population. We model the time to
disease progression t with the survival function such that
S∗(t) = θ + (1− θ)S(t),
where S(t) is the survival function for the non-cured sub-population. We assume
Weibull distribution for the time to disease progression in the non-cured patients
such that
S(t) = exp{−(λt)α}(4.1)
f(t) = αλ(λt)α−1 exp{−(λt)α}
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where f(t) is the density function of t. At an interim look, the disease progression
of each patient may not be observed. Let δi denote the censoring status of the i
th
patient at the observation time ti, where δi = 0 indicates censored observation. Then
the likelihood function of the ith patient with the event time ti is
[(1− θ)f(ti)]δi [θ + (1− θ)S(ti)]1−δi ,
where f(ti) and S(ti) are given by equation 4.1.
4.2.2 Prior specification and posterior estimation
For the Dirichlet prior of pi, we set
∑4
k=1 ak = 1 such that the prior is vague
and equivalent to a prior effective sample size of 1. Since the response of PD in the
first cycle of treatment indicates failure in curing patients, the cure rate θ is no larger
than pi1 + pi2 + pi3. Thus, we assign a uniform prior to θ such that
θ ∼ U(0, a1 + a2 + a3).
We assign the Gamma priors to the parameters of Weibull distribution (equa-
tion 4.1) α and λ as follows,
α ∼ Ga(aα, bα)
λ ∼ Ga(aλ, bλ)
We set the shape parameters as aα = 0.1, aλ = 0.05, and rate parameters as bα =
bλ = 0.1, such that the priors are vague.
At each interim look, we update the posterior estimates of pi, θ, α and λ,
using the Adaptive Rejection Metropolis Sampling within Gibbs Sampling (ARMS)
algorithm [59]. Suppose at the interim n patients have been enrolled, and the number
of patients with responses CR, PR, SD and PD are n1, n2, n3, and n4, respectively.
At each iteration, we conduct following steps:
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1. Update pi|· ∼ Dirichlet(a1+n1, . . . , a4+n4), with the truncation that pi1+pi2+
pi3 ≥ θ.
2. Update θ|· ∝
n∏
i=1
[(1− θ)f(ti|α, λ)]δi [θ + (1− θ)S(ti|α, λ)]1−δi , with the trunca-
tion that θ ≤ pi1 + pi2 + pi3.
3. Update α|· ∝
n∏
i=1
[(1− θ)f(ti|α, λ)]δi [θ + (1− θ)S(ti|α, λ)]1−δi×αaα−1 exp(−bαα).
4. Update λ|· ∝
n∏
i=1
[(1− θ)f(ti|α, λ)]δi [θ + (1− θ)S(ti|α, λ)]1−δi×λaλ−1 exp(−bλλ).
4.2.3 Trial Design
Same as the BOP2 design, The proposed BOP2-C design consists of R interim
looks, which occur when the number of enrolled patients reaches n1, · · · , nR, and a
final look when all N patients are enrolled. That is to say, the patients are enrolled
in R + 1 cohorts of size n1, n2 − n1, ..., nR − nR−1 and N − nR, respectively, and
the go/no-go decision is made after each cohort is enrolled. For notational brevity,
we suppress the subscript of the interim sample size, using n to denote each interim
sample size globally. Let C(n) denote a probability cutoff, which is a function of
the interim sample size n. Under the BOP2-C design, the go/no-go decision at each
interim is made based on the posterior estimation of the CR, CR/PR and cure rates,
respectively. Specifically, the proposed design would terminate the trial at an interim
look if:
Pr(pi1 ≤ φ1|Dn) > C(n) and
Pr(pi1 + pi2 ≤ φ2|Dn) > C(n) and
Pr(θ ≤ φ3|Dn) > C(n).
φ1, φ2, φ3 are pre-specified thresholds which are usually elicited from clinicians to
reflect the null hypothesis H0 that the treatment is futile. The clinicians also need
56
to specify a alternative hypothesis H1 under which the treatment is regarded as
promising. An example of the null/alternative hypotheses state that:
H0 : pi1 = 0.15, pi1 + pi2 = 0.30, θ = 0.1
H1 : pi1 = 0.25, pi1 + pi2 = 0.50, θ = 0.2
The type I error rate and statistical power are defined as the probability of rejecting
H0 under H0 and H1, respectively.
We use the same function for C(n) as the BOP2 design such that
(4.2) C(n) = 1− λc(n/N)γ,
where λc and γ are tuning parameters. As described in section 3.2.3, to select
optimized tuning parameters, we can either (1) maximize the power while controlling
the type I err rate given the fixed maximum sample size N , or (2) minimize the
expected sample size under H0 while controlling type I and II error rates given
unfixed maximum sample size.
4.3 Simulation study
4.3.1 Operating characteristics
We conducted numeric studies to evaluate the operating characteristics of the
proposed design. We specify the maximum sample size N = 120, and make go/no-go
decisions at the interims n = 40 and 80. In other words, we enroll three cohorts of
patients with cohort size 40, and make interim decisions after each cohort. We assume
the arrival time of the patients follows Poisson process, and one cohort of patients,
i.e., 40 patients are enrolled within 6 months. We assume the first cycle of treatment
is 1 month. That is to say, the tumor response can be fully observed within 1 month
for each patient. We make the interim go/no-go decision after the response result
57
of the last patient in cohort is observed, i.e., 1 month after the patient is enrolled
into the trial. We assume Weibull distribution for the time to disease progression in
non-cured patients. At the time 1 month, the observation of PD indicates disease
progression. Thus we have the survival function for the time to disease progression
in non-cured patients at 1 month is
S(1) = 1− pi4
1− θ ,
where pi4 and θ are the true PD rate and cure rate, respectively. Also we assume that
95% of the non-cured patients will experience disease progression within 6 month,
i.e., S(6) = 0.05. Therefore, we can determine the pair of Weibull parameters for
each scenario to simulate the time to disease progression of each patient.
To evaluate the performance of the designs, we considered the following three
metrics. (1) The percentage of rejecting the null hypothesis (PRN) is defined as the
percentage of the simulated trials in which H0 is rejected. The PRN is actually the
empirical type I error rate (or power) when H0 is (or is not) true. The PRN can be
also explained as the percentage of claiming that the new treatment is promising. (2)
The percentage of early termination (PET) is defined as the percentage of trials that
are terminated early. (3) The actual sample size is defined as the average sample
size across 10,000 simulated trials.
Table 4.1 shows the simulation results. The null hypothesis is scenario 1, i.e.,
H0 : pi1 = 0.15 and pi1 + pi2 = 0.35 and θ = 0.10, and the alternative hypothesis is
scenario 5, i.e., H1 : pi1 = 0.20 and pi1 + pi2 = 0.25 and θ = 0.15. For the proposed
BOP2-C design, We controlled the type I error rate at 0.1, and maximizes the power
to get the optimized design parameters. We compared the BOP2-C design with
the Thall and Simon’s design (TS design) [33], which only monitors the posterior
probability of CR/PR response rate, as is often done in practice. Thus, the TS
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design employed the beta-binomial model and terminated the trial if Pr(pi1 + pi2 ≤
0.35|Dn) > C, where C is a fixed cutoff. We calibrated the value of C to control the
type I error rate of the TS design at 0.1.
As shown in Table 4.1, the BOP2-C design generally has more power than
the TS design. For example, under the alternative hypothesis scenario 5, the power
of the BOP2-C design is 90.1%, compared to 64.0% for the TS design. For scenario
2, the only difference with scenario 1 is that we reversed the values of CR and PR
rate. Under this scenario, the PRN of the BOP2-C design should increase because
the CR rate is greater than 0.15 while other two remain the same. As expected,
the PRN increases to 46.4%, and the trial is slightly less likely to stop early. For
the TS design, however, it cannot distinguish scenarios 1 and 2, because the CR/PR
rate remains the same. For scenario 3, although the CR rate is less than 0.15 and
CR/PR rate is less than 0.35, the cure rate is higher than 0.1. Thus, our design
still yields higher power (PRN = 59.1%), while the TS design almost never claims
the new treatment is promising (PRN = 0.7%). The comparison among the first
three scenarios indicate that the BOP2-C design actually meets our expectation to
monitor CR, CR/PR and cure rates simultaneously.
4.3.2 Sensitivity analysis
We also conducted the sensitivity analysis to evaluate the performance of
BOP2-C design when the time to disease progression in the non-cured patients does
not follow the Weibull distribution. Table 4.2 shows the simulation results when the
time to disease progression follows the log-logistic distribution, in contrast to the
results shown in Table 4.1. We can see under different assumptions of the time to
disease progression, the results are similar to each other in most of the scenarios,
especially in terms of the power of design, which indicates that our proposed design
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is robust.
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Table 4.1: Percentage of rejecting the null (PRN), percentage of early termination (PET), and
the actual sample size under the BOP2-C design and TS design (Thall and Simon, 1994). Interim
sample sizes are 40, 80, 120.
PRN(%) PET(%) Sample size
Scenario pi θ BOP2-C TS BOP2-C TS BOP2-C TS
1 (0.15,0.20,0.30,0.35)§ 0.10 9.4 9.4 63.7 88.1 72.0 52.9
2 (0.20,0.15,0.30,0.35) 0.10 46.4 9.2 17.5 88.3 110.6 52.7
3 (0.10,0.20,0.30,0.40) 0.15 59.1 0.7 7.8 98.3 115.6 43.2
4 (0.15,0.25,0.30,0.30) 0.15 70.9 34.4 3.7 63.6 118.0 72.1
5 (0.20,0.25,0.30,0.25)† 0.15 90.1 64.0 1.4 35.5 119.2 92.9
6 (0.20,0.25,0.30,0.25) 0.20 98.5 63.9 0.3 35.6 119.9 92.9
7 (0.25,0.20,0.30,0.25) 0.15 95.7 64.7 0.7 64.7 119.6 93.5
§: null hypothesis; †: alternative hypothesis.
Table 4.2: Percentage of rejecting the null (PRN), percentage of early termination (PET), and the
actual sample size of the BOP2-C design under Weibull and Log-logistic assumptions of time to
disease progression.
PRN(%) PET(%) Sample size
Scenario pi θ Weib Log-L Weib Log-L Weib Log-L
1 (0.15,0.20,0.30,0.35)§ 0.10 9.4 9.8 63.7 60.4 72.0 78.5
2 (0.20,0.15,0.30,0.35) 0.10 46.4 32.4 17.5 42.8 110.6 92.2
3 (0.10,0.20,0.30,0.40) 0.15 59.1 55.6 7.8 20.1 115.6 106.9
4 (0.15,0.25,0.30,0.30) 0.15 70.9 66.4 3.7 11.2 118.0 113.1
5 (0.20,0.25,0.30,0.25)† 0.15 90.1 85.0 1.4 6.2 119.2 116.2
6 (0.20,0.25,0.30,0.25) 0.20 98.5 96.9 0.3 1.7 119.9 118.8
7 (0.25,0.20,0.30,0.25) 0.15 95.7 92.0 0.7 4.1 119.6 117.2
§: null hypothesis; †: alternative hypothesis.
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CHAPTER 5
Conclusion and Future Work
In chapter 2, we evaluated the operating characteristics of some novel Bayesian
phase I trial designs in terms of accuracy, overdose control and reliability. Compared
to the 3+3 design, most of these novel designs yield better accuracy for identify-
ing the MTD and allocate more patients to the MTD. Overall, CRM performs well
in most metrics. Allowing dose skipping slightly improves the accuracy for iden-
tifying the MTD and the allocation of patients to the MTD, but at the cost of
substantially increasing the number of overdosed patients and decreasing the design
reliability (i.e., a higher risk of overdosing a large percentage of patients). Thus, dose
skipping in CRM is generally not recommended, and we suggest restricting dose es-
calation and de-escalation to one dose level at a time. The performance of BLRM is
mixed. BLRM (with the overdose control rule) is excessively conservative and has
poor accuracy to identify the MTD and allocate patients to the MTD. Removing
the overdose control rule (i.e., BLRM-NOC) improves the accuracy to identify the
MTD and allocate patients to the MTD, but at the cost of substantially reduced
safety (i.e., treating a high percentage of patients above the MTD) and reliability
(i.e., high risk of overdosing a large percentage of patients). The overdose control
rule commonly used in BLRM seems to be too conservative, and a more appropri-
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ate overdose control rule may be needed to make BLRM work appropriately. The
EWOC appears overly conservative. It is safe, but has poor accuracy to identify the
MTD. The EWOC has similar average performance as the BLRM, but has larger
variation. The model-assisted designs BOIN and keyboard yield good performance
that is generally comparable to that of the CRM in terms of accuracy and safety,
while often providing smaller variation and better reliability. The mTPI performs
well in identifying the MTD and allocating patients to the MTD when the target
DLT probability is 0.25, but has lower reliability with a higher risk of overdosing a
large percentage of patients and poor allocation of patients to the MTD. The mTPI
has a relatively low accuracy to identify the MTD when the target DLT probability is
0.2. Given that BOIN and keyboard are more transparent and simple to implement,
they provide attractive approaches to designing phase I clinical trials. The BOIN
and keyboard designs have virtually the same performance in every metric. As the
BOIN uses the observed DLT rate to determine dose escalation and de-escalation, it
is more transparent and assessable for non-statisticians, and is easier to calibrate to
fit the design goal. In addition, as noted by a referee, the BOIN has both Bayesian
and frequentist interpretations. Its decision rule is equivalent to using the likelihood
ratio test to determine dose escalation/de-escalation [19], making it appealing to
wider audiences. In contrast, the mTPI/mTPI2 and keyboard designs only have a
Bayesian interpretation and require specification of the prior and calculation of the
posterior distribution.
In our Monto Carlo experiment, we used the default design parameters recom-
mended by the designs that are tailored to the “non-informative” case where limited
prior knowledge is available on the toxicity profile of the investigational drug. This
is appropriate for evaluating and comparing the general performance of the designs
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across a variety of toxicity profiles, and for first-in-human drug trials. For the “me-
too” or same-family drugs with a better known toxicity profile, the design parameters
should be calibrated based on the available prior information to fit the trial under
consideration. For example, if the prior information suggests that the investigational
drug is relatively safe, we can choose the design parameters that encourage more
aggressive dose escalation to find the MTD quickly.
The designs reviewed here focus on single-agent trials and require that be-
fore enrolling the next cohort of new patients, patients who were enrolled into the
trial have completed their DLT assessment. This requirement is troublesome when
toxicity is late-onset or the accrual is fast. Extension of these novel designs, have
been developed to address the late-onset toxicity, e.g., the TITE-CRM [10] and data-
augmentation CRM [12], and to handle drug combination trials [60, 13, 61, 21, 24].
Recently, Clertant and O’Quigley [46] propose a flexible semiparametric dose finding
methods that reduces to the CRM under some added parametric conditions, and
is equivalent to the mTPI or BOIN design under some relaxation of the underly-
ing structure. The semiparametric dose finding method shows competitive perfor-
mance. Comprehensively investigating the existing phase I designs under such a
unified framework is of interest and warrants further research.
In chapter 3, we proposed a flexible Bayesian optimal design for phase II
trials (BOP2) with simple and complex endpoints under a unified framework, and
in chapter 4 we extended it to the BOP2-C design which simultaneously monitors
the first cycle tumor response rate and the long-term durable response rate (cure
rate). Our BOP2 (BOP2-C) design can explicitly control the type I and II error
rates, thereby bridging the gap between Bayesian designs and frequentist designs. In
addition, unlike many existing Bayesian designs which use the posterior probability
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to make go/no-go decision, the BOP2 design allows the posterior probability cutoff
to vary with the interim sample size, which improves the power of the design and re-
duces the probability of incorrectly terminating the trial early when the treatment is
actually promising. Another important feature of the BOP2 design is that the stop-
ping boundaries can be enumerated prior to the onset of trial, making it particularly
easy to implement in practice.
The BOP2 design requires the response of each patient can be observed in a
very short period after the patient is enrolled into the trial. However, in practice,
sometime we need a long time to evaluate the clinical response of patients. If this
happens, the patient accrual may be suspended until the results of previous patients
are fully observed. In order to shorten the trial time under the circumstances of
such delayed responses, we can extend the BOP2 design using the similar method
proposed by Cai et al. [62]. Also, extending the BOP2 design from the categorical
endpoints to time-to-event endpoints warrants further investigation.
In this dissertation, we studied phase I and phase II clinical trial designs sep-
arately. Numerous phase I/II designs have also been proposed to simultaneously
consider toxicity and efficacy by combining dose-finding methods and interim de-
cision making together. Thall and Russell (1998) proposed a phase I/II design to
characterize the patient outcome with a trinary ordinal variable which account for
both toxicity and efficacy [63]. Thall and Cook (2004) introduced a Bayesian phase
I/II design based on evaluating the trade-offs between toxicity and efficacy [64]. Yin
et al. (2006) proposed a Bayesian dosing-find method using the odds ratios between
toxicity and efficacy for phase I/II clinical trials [65]. Yuan and Yin (2009, 2011)
developed a phase I/II design to jointly model toxicity and efficacy as time-to-event
outcomes, and a Bayesian phase I/II design for drug-combination trials [66, 67]. Liu
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et al. recently proposed the first Bayesian phase I/II trial design for immunother-
apy, which simultaneously models the immune response, toxicity, and efficacy [68].
The phase I/II trials designs accounting for immunotherapeutic endpoints warrants
future work.
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